Search COVID-19 Rapid Resource Center or explore resources sorted by Category or Content Type.

 

Category: Pharmacology

NIH Resource: The COVID-19 Treatment Guidelines Panel’s Interim Statement on Patient Prioritization for Outpatient Anti-SARS-CoV-2 Therapies or Preventive Strategies When There Are Logistical or Supply Constraints

The COVID-19 Treatment Guidelines Panel (the Panel) has recommended several therapeutic agents for the treatment and prevention of SARS-CoV-2 infection in individuals who are at high risk for progression to severe COVID-19. These anti-SARS-CoV-2 therapeutics are of greatest be...

WHO Resource: WHO Therapeutics and COVID-19: living guideline

The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via ...

   Estimated Time: Coronavirus, COVID-19, Therapies

FDA Resource: Paxlovid received EUA approval from the FDA

December 22, 2021, the FDA issued an emergency use authorization (EUA) for Pfizer’s Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate coronavirus disease (COVID-19) in adults and pediatric patients (12 years o...

   Estimated Time: Coronavirus, COVID-19, Therapies

FDA Resource: Molnupiravir received EUA approval from the FDA

The FDA has granted molnupiravir emergency use authorization (EUA) to treat mild to moderate COVID-19 in adults at high risk of severe illness. High risk people include adults aged 65 and over and people with certain medical conditions. The FDA also states that molnupiravir sh...

   Estimated Time: Coronavirus, COVID-19, Therapies

Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group

From Critical Care Explorations . In this study the authors found that hospital variation in the use of repurposed medications varied widely across hospitals early in the pandemic and later converged with the emergence of randomized clinical trials. 

   Estimated Time: 22:39 min Coronavirus, COVID-19

Update on Current Approved Therapies for COVID-19

Stay up to date on the mass vaccination efforts in the United States with this SCCM webcast. Thought leaders will address current COVID-19 variants and vaccine efficacy and review pediatric vaccination considerations. This webcast is the second in a series of updates that SCCM...

   Estimated Time: 1:01:15 Coronavirus, COVID-19, Therapies

COVID-19 Vaccine Update

Stay up to date on the mass vaccination efforts in the United States with this FREE SCCM webcast. Thought leaders will address current COVID-19 variants and vaccine efficacy and review pediatric vaccination considerations. This webcast is the second in a series of updates that...

   Estimated Time: 1:02:27 Coronavirus, COVID-19, Vaccines

Critical Impact: COVID-19: Highlights Session 1

This webinar covers highlights from the Critical Impact: Clinical Practice course.

Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial

From Critical Care Medicine .  In this study, the authors explored candidate prognostic and predictive biomarkers identified in retrospective observational studies (interleukin-6, C-reactive protein, lactate dehydrogenase, ferritin, lymphocytes, monocytes, neutrophils, D-dime...

   Estimated Time: 27:41 min Coronavirus, COVID-19

UCHealth COVID-19 Pharmacotherapy Guidance

This community developed resource is a quick reference guide for utlization of various COVID-19 pharmacotherapies.

   Estimated Time: 18:21 min Coronavirus, COVID-19, Therapies

Accelerating Coronavirus Disease 2019 Therapeutic Interventions and Vaccines—Selecting Compounds for Clinical Evaluation in Coronavirus Disease 2019 Clinical Trials

From Critical Care Medicine . In this Review Article the authors established a uniform data collection process required to perform an assessment of any agent type using review criteria that were identified and differentially weighted for each agent class,

   Estimated Time: 24:36 min Coronavirus, COVID-19, Therapies

Can you comment on any current literature on the use of IV vitamin C, as well as ivermectin?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

   Estimated Time: 0:47 min Coronavirus, COVID-19

When monitoring hospitalized COVID-19 patients, both critically ill and noncritically ill, to prevent Stenotrophomonas or other secondary infections or fungal infections, when should prophylactic antibiotics be administered?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

   Estimated Time: 2:12 min Coronavirus, COVID-19, Therapies

What suggestions do you have for pharmacists, physician assistants, nurses, and physicians who work in a traditionally non-ICU environment who want to obtain further skills and knowledge to care for critically ill, difficult-to-manage patients?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

   Estimated Time: 1:44 min Coronavirus, COVID-19, Resource Allocation

When should paralytics be initiated, when should they be weaned off, and how do you decide whether to monitor neuromuscular blockade?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

   Estimated Time: 4:27 min Coronavirus, COVID-19, Sedation

Regarding fluid management, inotropes, and vasopressors in critically ill patients, which drugs are concerning with excessive fluid volume?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

   Estimated Time: 5:12 min Coronavirus, COVID-19, Supportive Care

What are the current recommended treatments for critically ill patients with COVID-19?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 8, 2021

   Estimated Time: 4:48 min Coronavirus, COVID-19, Therapies

Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease 2019

From Critical Care Explorations . In this study, the authors conclude that argatroban, with or without aspirin, is an effective anticoagulation strategy for patients who require venovenous extracorporeal membrane oxygenation support secondary to coronavirus disease 2019.

   Estimated Time: 20:16 min Anticoagulation, Coronavirus, COVID-19, ECMO

Plasma Exchange in Patients With Severe Coronavirus Disease 2019: A Single-Center Experience

From Critical Care Explorations . The data in this study provide further evidence for plasma exchange as a novel therapeutic strategy in a subset of critically ill coronavirus disease 2019 patients by potentially reversing the complex coronavirus disease 2019 immunopathology.

   Estimated Time: 25:10 min Convalescent Plasma Therapy, Coronavirus, COVID-19

What is the most appropriate broad-spectrum antibiotic for a patient with a superimposed infection while in the hospital with COVID-19?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on August 11, 2021

   Estimated Time: 01:52 min Coronavirus, COVID-19, Therapies